65,437 trials
Rheumatoid Arthritis
Primary: Percentage of Participants With Clinically Significant Improvement in Health Assessment Questionnaire - Disability Index (HAQ-DI) at Week 4 — 42.0; 49.1 percentage of…
Fibrosis · Kidney Failure · Renal Insufficiency
Primary: Number of Participants Who Developed Nephrogenic Systemic Fibrosis (NSF), Based on Diagnostically Specific Clinical and Histopathological Information-cohort Analysis and…
Type 1 Diabetes Mellitus
Primary: Area Under the Curve for Glucose Above Baseline — 0.623; 0.59; 0.03 mg/kg glucose per mcg glucagon
Lung Cancer
Primary: Determine the Clinical Sensitivity and Specificity of the Biomoda CyPath™ Early Lung Cancer Detection Assay Using Sputum Specimens From Two Cohorts of Participants and…
Overactive Bladder
Primary: Mean Change of the Total Frequency Per 3 Days — -4.64; -0.19 Frequency per 3 days
Recurrent Non-small Cell Lung Cancer
Primary: Response Rate (Complete and Partial) 2 Separate Cohorts of Relapsed NSCLC Cohort A: Pts Who Have Received Prior Chemo w/o Ever Having Received Bevacizumab. Cohort B: Pts…
Osteoporosis
Primary: Serum Markers of Skeletal Turnover (Serum CTX) — 0.9887; 0.5445 ng/mL
Leukemia, Myeloid, Acute
Primary: Phase I Only: Optimal Dose of AMD3100 Plus MEC in Patients With Relapsed or Refractory AML — 240 mcg/kg
Major Depressive Disorder
Primary: Number of Dose Limiting Toxicity of Physical Examination — 0; 0 participants
Bacterial Meningitis
Primary: Percentage of Overall Subjects With Seroresponse, Directed Against Neisseria Meningitidis Serogroups A, C, W and Y After MenACWY-CRM Vaccination — 83; 93; 50; 65…
Alcohol Dependence
Primary: % BOLD Response Increase Above Baseline — .106; .082; .074; .097 % BOLD Response increase above baseline — p==.05
Vitamin D Deficiency · End-stage Renal Disease
Primary: Change in 25OH-Vitamin D Level — 15.8; 40.9 ng/dL
Inflammation Associated With Cataract Surgery
Primary: Anterior Chamber Cell Count at Day 8 Post-Treatment — 50; 51.8; 60.3 percentage of patients with ACC clearing
Cervical Degenerative Disc Disease
Primary: Rate of Overall Success — 70.4; 63.2 percentage of participants — p=0.995
Crohn's Disease
Primary: Number of Participants With Improved in Disease Activity — 0 participants